Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Atezolizumab vs best supportive care in resected NSCLC

Dr Enriqueta Felip - Vall d'Hebron University Hospital, Barcelona, Spain

Atezolizumab vs best supportive care in resected NSCLC ( Dr Enriqueta Felip - Vall d'Hebron University Hospital, Barcelona, Spain )

MOUNTAINEER: Tucatinib in combination with trastuzumab for HER2-positive mCRC

Dr Jonathan Strickler - Duke Cancer Institute, Durham, USA

MOUNTAINEER: Tucatinib in combination with trastuzumab for HER2-positive mCRC ( Dr Jonathan Strickler - Duke Cancer Institute, Durham, USA )

Working to improve global cancer care access in low middle-income countries

Dr Julie Gralow, Prof Eduardo Cazap

Working to improve global cancer care access in low middle-income countries ( Dr Julie Gralow, Prof Eduardo Cazap )

Impact of BRAF-V600E mutation on the tumour microenvironment and associated...

Dr Mohamed Salem - Levine Cancer Institute, Charlotte, USA

Impact of BRAF-V600E mutation on the tumour microenvironment and associated genomic alterations in colorectal cancer ( Dr Mohamed Salem - Levine Cancer Institute, Charlotte, USA )

Low-dose nivolumab leads to improved overall survival for head and neck cancer...

Dr Bishal Gyawali - Queen's University, Kingston, Canada

Low-dose nivolumab leads to improved overall survival for head and neck cancer patients ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

Palbociclib shows improved PFS but not improved OS for ER+ HER2- mBC patients

Dr Bishal Gyawali - Queen's University, Kingston, Canada

Palbociclib shows improved PFS but not improved OS for ER+ HER2- mBC patients ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

Updates from the PROpel and MAGNITUDE studies

Prof Phil Cornford and Dr Elena Castro

Updates from the PROpel and MAGNITUDE studies ( Prof Phil Cornford and Dr Elena Castro )

Update on the latest in PARP inhibitors for prostate cancer

Prof Axel Merseburger and Prof Bertrand Tombal

Update on the latest in PARP inhibitors for prostate cancer ( Prof Axel Merseburger and Prof Bertrand Tombal )

Prostate roundup what have we learned from EAU and ASCO 2022?

Prof Eleni Efstathiou and Prof Nicolas Mottet

Prostate roundup what have we learned from EAU and ASCO 2022? ( Prof Eleni Efstathiou and Prof Nicolas Mottet )

Isatuximab + Pd in Difficult-to-Treat Patients with RRMM

Dr Maximilian Merz - Leipzig University, Leipzig, Germany

Isatuximab + Pd in Difficult-to-Treat Patients with RRMM ( Dr Maximilian Merz - Leipzig University, Leipzig, Germany )

ASCO Direct Highlights 2022: prostate cancer highlights

Dr Chandler Park - Baptist Health Hardin, Elizabethtown, USA

ASCO Direct Highlights 2022: prostate cancer highlights ( Dr Chandler Park - Baptist Health Hardin, Elizabethtown, USA )

ASCO Direct Highlights 2022: lung cancer highlights

Dr Tom Stinchcombe - Duke Cancer Center, Durham, USA

ASCO Direct Highlights 2022: lung cancer highlights ( Dr Tom Stinchcombe - Duke Cancer Center, Durham, USA )

More from ecancer